Abstract: The invention provides a (drug-containing) lipid nanoparticle with: (i) at least one phospholipid; (ii) at least one lysolipid; and (iii) at least one phospholipid comprising a hydrophilic polymer; and (iv) at least one structural lipid of formula (I) which has the following general structure: wherein R and R? are long hydrocarbyl hydrophobic chains, Y is a linker element, and PHG is a polar head group described as large according to its van der Waals radius, and which is different from the phospholipid (i). The lipid nanoparticle can release a drug (or API) from within the lipid nanoparticle as a result of focused ultrasound (FUS) applied continuously, at least twice, to a desired part of the body to induce hyperthermia (an increase in temperature). FUS is applied after the lipid nanoparticle containing the drug has been administered to the live subject, and causes controlled release of the drug at the desired site of the body.

Abstract: The present invention provides novel liposomes comprising Gd.DOTA.DSA (gadolinium (III) 2-{4,7-bis-carboxymethyl-10-[(N,N-distearylamidomethyl-N?-amido-methyl]-1,4,7,10- =tetra-azacyclododec-1-yl}-acetic acid), characterised in that the liposome further comprises a neutral, fully saturated phospholipid component (e.g. DSPC (1,2-distearoyl-sn-glycero-3-phospocholine]), which are of particular use in the preparation of magnetic resonance contrast agents for enhancing a magnetic resonance image of tumours in a mammal.

Abstract: The invention relates to a hyperthermia (focused ultrasound—FUS) method where an energy source is applied, repeatedly, to a desired part of the body to induce hyperthermia, e.g. using image guidance. Hyperthermia is applied after a drug or biopharmaceutical (API) and/or their labelled equivalents (theranostics) and/or their drug delivery systems has been administered to the live subject to cause the enhanced tissue distribution and/or controlled release of the drug, previously encapsulated in thermo-sensitive (lipid nano)particles, to a desired site of the body. Hyperthermia (Ultrasound) is then halted, and the site of interest. Hyperthermia is then applied again using image guidance to monitor drug's accumulation in the tissue. The drug and or the drug delivery system are also labelled (for imaging) to allow real time monitoring and modulation of the API in the human body which can be used to direct and guide the FUS at the site of interest.

Abstract: The invention provides a (drug-containing) lipid nanoparticle with: (i) at least one phospholipid; (ii) at least one lysolipid; and (iii) at least one phospholipid comprising a hydrophilic polymer; and (iv) at least one structural lipid of formula (I) which has the following general structure: wherein R and R? are long hydrocarbyl hydrophobic chains, Y is a linker element, and PHG is a polar head group described as large according to its van der Waals radius, and which is different from the phospholipid (i). The lipid nanoparticle can release a drug (or API) from within the lipid nanoparticle as a result of focused ultrasound (FUS) applied continuously, at least twice, to a desired part of the body to induce hyperthermia (an increase in temperature). FUS is applied after the lipid nanoparticle containing the drug has been administered to the live subject, and causes controlled release of the drug at the desired site of the body.

Abstract: The present invention provides novel liposomes comprising Gd.DOTA.DSA (gadolinium (III) 2-{4,7-bis-carboxymethyl-10-[(N,N-distearylamidomethyl-N?-amido-methyl]-1,4,7,10-tetra-azacyclododec-1-yl}-acetic acid), characterised in that said liposome further comprises a neutral, fully saturated phospholipid component (e.g. DSPC (1,2-distearoyl-sn-glycero-3-phospocholine]), which are of particular use in the preparation of magnetic resonance contrast agents for enhancing a magnetic resonance image of tumours in a mammal.

Abstract: The present invention relates to a mucoadhesive carrier system, for particles, which comprises nanoscaffold having a nanofibrous layer with a thickness of from 0.1 to 1000 ?m, carrying a substance in the form of particles. The mucoadhesive layer, in at least a part of its surface, overlaps the nanoscaffold. A process for its preparation and its use for delivery of the vaccines and therapeutics to mucosal surfaces is also disclosed.

Abstract: The present invention relates to administration of a dinucleoside polyphosphate analogue or a pharmaceutically acceptable salt thereof, topically in a formulation comprising a suitable excipient or using a device for transdermal delivery, and/or combined with a nanoparticle carrier. The present invention also relates to the therapeutic use of such compositions or devices, in particular in the treatment of pain or epilepsy. The analogue may be combined with an anaesthetic (such as a salt form) or delivered in a nanoparticle.

Abstract: The invention provides a dinucleoside polyphosphate analogue, or a pharmaceutically acceptable salt thereof, for use as an anticonvulsant and/or seizure suppressant, in particular in the treatment or prevention of (e.g. juvenile) epilepsy.

Abstract: The invention provides a dinucleoside polyphosphate analogue, or a pharmaceutically acceptable salt thereof, for use in the inhibition (or down-regulation) of a pain, via a transducing ATP-gated P2X3 receptor, often by means of high-affinity desensitisation (HAD) mechanism.

Abstract: Identification technology, in which a request related to generating conveyable information for a particular vendor is received based on user input provided by a particular user and mappings stored in a database are searched using an identifier associated with the particular vendor. At least one rule useful in generating conveyable information for the particular vendor is determined based on results of the searching and identification information for a type of conveyable information requested by the particular user is determined. Conveyable information is generated by applying the determined at least one rule to the determined identification information. A mobile device outputs the generated conveyable information to enable identification of the type of conveyable information requested by the particular user to a system of the particular vendor through the output of the mobile device.

Abstract: The present invention provides novel liposomes comprising Gd.DOTA.DSA (gadolinium(III)2-{4,7-bis-carboxymethyl-10-[(N,N-distearylamidomethyl-N?-amido-methyl]-1,4,7,10-tetra-azacyclododec-1-yl}-acetic acid), characterised in that said liposome further comprises a neutral, fully saturated phospholipid component (e.g. DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine]), which are of particular use in the preparation of magnetic resonance contrast agents for enhancing a magnetic resonance image of tumours in a mammal.

Abstract: The present invention provides a lipid compound comprising at least one non-polar moiety and a polar moiety, wherein each or at least one non-polar moiety is of the formula X—Y—Z, wherein X is a hydrocarbyl chain, Y is selected from at least one of S, Se, SO2, SO, and O, and Z is an optional hydrocarbyl group, wherein the polar moiety is of the formula —[C(O)]mPHG, wherein PHG is a polar head group, and wherein m is the number of non-polar moieties.

Abstract: The present invention provides a lipid compound comprising at least one non-polar moiety and a polar moiety, wherein each or at least one non-polar moiety is of the formula X—Y—Z—, wherein X is a hydrocarbyl chain, Y is selected from at least one of S, Se, SO2, SO, and O, and Z is an optional hydrocarbyl group, wherein the polar moiety is of the formula —[C(O)]mPHG, wherein PHG is a polar head group, and wherein m is the number of non-polar moieties.

Abstract: The present invention provides a lipid of the formula (I) R3R4N—[Y]q—(CpH2p)—X-Linker-NR1R2 (I) wherein R3 and R4 are independently selected from H and hydrocarbyl groups; q is an integer selected from 1 to 10; Y represents a group (CnH2n)NR5, wherein (i) when q is 1, n is 2, or (ii) when q is greater than 1, each Y may be the same or different and each n is an integer independently selected from 1 to 10, with the proviso that for at least one unit Y, n is 2, and (iii) each R5 is independently selected from H and hydrocarbyl groups; p is an integer selected from 1 to 10; X is an optional group selected from —NR7—, —C(?O)—NR8—, —NR9—C(?O)—, —C(?O)—, —O—, and NR10—C(=0)0-, wherein each R7, R8, R9 and R10 is independently selected from H and hydrocarbyl groups, Linker is an optional group selected from amino acid residues, peptide residues and groups of the formula —(OCH2CH2)1-10, —NR6-(CvH2v)—C(?O)—, wherein R6 is H or a hydrocarbyl group and v is an integer selected from 1 to 11, and —C(=0)-(CH2)0-10—CH2—C(=0)

Abstract: The present invention provides the use of analogues and derivatives of dinucleoside polyphosphates with formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in one or more of: the treatment of ischemia, inducing ischemic tolerance, modulating cerebral ischemia, to delay the onset of a hypoxic depolarisation stage when ischemic events are initiated; as a neurological protection agent; as a tissue protection agent; the treatment of pain; and the treatment of inflammation, wherein X, is selected from wherein X1 and X2 are independently selected from H, Cl, Br and F; each Y is independently selected from S and O; each Z is independently selected from —CX3X4—,—NH—,—O—; wherein X3 and X4 are selected from H, Cl, Br and F; B1 and B2 are independently selected from adenine, guanine, xanthine, thymine, uracil, cytosine and inosine; S1 and S2 are independently selected from ribose, open chain ribose, 2?-deoxyribose, 3?deoxyribose and arabinofuranoside.

Abstract: The present invention relates to a non-viral delivery vector comprising a liposome, wherein one or more lipids of the liposome are coupled, reversibly or irreversibly, to one or more polymers, and wherein the liposome comprises siRNA.

Abstract: The present invention provides a composition comprising (i) a lipid compound comprising at least one non-polar moiety and a polar moiety, wherein the non-polar moiety is of the formula X-Y-Z- wherein X is an acetylenic hydrocarbyl group containing a single C≡C bond, Y is O or CH2, and Z is an optional hydrocarbyl group, wherein the polar moiety is of the formula -[T]mPHG, wherein [T]m is an optional group selected from C(O), NH, NR1, NHC(O), C(O)NH, NRIC(O) and C(O)NR1 and CH2, where R1 is a hydrocarbyl group, wherein PHG is a polar head group, and wherein m is the number of non-polar moieties (ii) a therapeutic agent.

Abstract: The present invention provides a compound capable of acting as a cationic lipid, the compound comprises a cholesterol group and a carbohydrate moiety.

Abstract: The present invention provides a compound of the formula 1